Diamyd Medical divests U.S. gene therapy company
October 08, 2012 02:30 ET
|
Mertiva
Diamyd Medical AB has entered into an agreement for the sale of the U.S.
subsidiary, Diamyd, Inc., involved in drug development primarily relating to the
NTDDS platform with applications in pain and...
Diamyd Medical avyttrar amerikanskt genterapibolag
October 08, 2012 02:30 ET
|
Mertiva
Diamyd Medical AB har tecknat ett avtal om avyttring av det amerikanska
dotterbolaget Diamyd, Inc., som bedriver läkemedelsutveckling, främst avseende
den så kallade NTDDS-plattformen med...
Delårsrapport III 11/12
July 03, 2012 02:30 ET
|
Mertiva
september 2011 – maj 2012
Delårsrapport Diamyd Medical AB (publ), räkenskapsåret 2011/2012
(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)
Perioden 1 mars 2012 – 31 maj 2012
·...
Quarterly Report III 11/12
July 03, 2012 02:30 ET
|
Mertiva
September 2011 – May 2012
Quarterly Report Diamyd Medical AB (publ), fiscal year 2011/2012
(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker: DMYDY)
Reporting period March 1, 2012 – May 31,...
Diamyd Medical reports results from Phase II study in cancer pain
July 03, 2012 02:00 ET
|
Mertiva
Diamyd Medical AB reports that a Phase II study evaluating the Company’s drug
candidate NP2 Enkephalin did not meet its primary objective of reducing pain in
subjects with severe intractable cancer...
Diamyd Medical redovisar resultat från fas II-studie i cancersmärta
July 03, 2012 02:00 ET
|
Mertiva
Diamyd Medical AB meddelar att en fas II-studie som utvärderar bolagets
läkemedelskandidat NP2 Enkefalin inte uppnådde det primära syftet att visa
smärtlindring i patienter med allvarlig och...
Diamyd Medical's Phase II study in cancer pain fully recruited
May 22, 2012 02:30 ET
|
Mertiva
The last study participant has been recruited to Diamyd Medical’s Phase II study
in which cancer pain is treated with the drug candidate NP2 Enkephalin. The
study is thus fully enrolled and results...
Diamyd Medicals fas II-studie i cancersmärta fullrekryterad
May 22, 2012 02:30 ET
|
Mertiva
Den sista deltagaren har rekryterats till Diamyd Medicals fas II-studie där
cancersmärta behandlas med läkemedelskandidaten NP2 Enkefalin. Studien är därmed
fullrekryterad och resultat beräknas kunna...
Quarterly Report II 11/12
April 04, 2012 02:30 ET
|
Mertiva
September 2011 – February 2012
Quarterly Report Diamyd Medical AB (publ),
fiscal year 2011/2012
(www.omxgroup.com ticker: DIAM B; www.otcqx.com ticker:
DMYDY)
Reporting period December 1, 2011 –...
Delårsrapport II 11/12
April 04, 2012 02:30 ET
|
Mertiva
september 2011 – februari 2012
Delårsrapport Diamyd Medical AB (publ),
räkenskapsåret 2011/2012
(www.omxgroup.com ticker: DIAM B; www.otcqx.com
ticker: DMYDY)
Perioden 1 december 2011 – 29 februari...